Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A Multicenter, Double-blind, Placebo-controlled, Cross-over, Multiple (n=1) Trial.

NCT05724069 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT05724069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05724069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A Multicenter, Double-blind, Placebo-controlled, Cross-over, Multiple (n=1) Trial.
Lead sponsor
Alfasigma S.p.A.
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2021
Completion date
April 12, 2023
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic intestinal pseudo-obstruction